Share Price and Basic Stock Data
Last Updated: January 20, 2026, 10:14 pm
| PEG Ratio | -13.60 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Thyrocare Technologies Ltd operates in the Hospitals & Medical Services industry, currently priced at ₹465 with a market capitalization of ₹7,396 Cr. The company reported revenues of ₹708 Cr for the trailing twelve months (TTM), reflecting a steady upward trend from ₹562 Cr in FY 2022. Revenue has shown consistent quarterly growth, with sales rising from ₹125 Cr in September 2022 to ₹136 Cr in September 2023. The revenue trend indicates resilience, particularly in the context of post-pandemic recovery, as sales are projected to continue growing, reaching ₹202 Cr by September 2025. This aligns with the industry’s recovery trajectory, where many companies have witnessed a rebound in demand for healthcare services. Thyrocare’s operating profit margin (OPM) stood at 34%, illustrating its strong cost management and operational efficiency relative to industry standards. Overall, the company’s revenue growth trajectory positions it favorably within the competitive landscape of healthcare services in India.
Profitability and Efficiency Metrics
Thyrocare’s profitability metrics reveal a robust operational framework, with a reported net profit of ₹120 Cr and a return on equity (ROE) of 17.4%. The net profit margin was recorded at 13.41% for FY 2025, indicating effective cost controls and pricing strategies. The company’s operating profit margin (OPM) has shown resilience, fluctuating between 24% and 34% over the past quarters, with a notable increase to 34% by September 2025. Efficiency metrics also highlight a cash conversion cycle (CCC) of -9 days, underscoring Thyrocare’s ability to convert its investments into cash quickly, significantly better than typical sector benchmarks. The interest coverage ratio (ICR) stood at an impressive 67.28x, reflecting minimal debt obligations and strong earnings, which enhances the company’s ability to manage financial costs. These figures collectively indicate a strong operational performance, positioning Thyrocare as a profitable player in the healthcare services market.
Balance Sheet Strength and Financial Ratios
Thyrocare’s balance sheet demonstrates considerable strength, with total assets amounting to ₹676 Cr and minimal borrowings of ₹22 Cr, resulting in a debt-to-equity ratio of 0.00. This indicates a conservative capital structure, which is beneficial for financial stability and reduces risk exposure. The company has maintained reserves of ₹463 Cr, which provides a cushion for future growth initiatives. Key financial ratios are favorable, with a return on capital employed (ROCE) of 26.5% and a price-to-book value (P/BV) ratio of 6.59x, suggesting that the market values Thyrocare’s equity significantly. Additionally, the current ratio of 2.77 indicates strong liquidity, allowing the company to meet its short-term obligations comfortably. The overall financial health is solid, positioning Thyrocare for potential expansion and investment opportunities while also mitigating financial risks.
Shareholding Pattern and Investor Confidence
The shareholding structure of Thyrocare Technologies Ltd reflects a mix of institutional and retail investor confidence. Promoters hold 60.93% of the company, indicating a strong commitment from the management. The shareholding of Foreign Institutional Investors (FIIs) has increased to 5.32%, while Domestic Institutional Investors (DIIs) hold 20.16%, suggesting a growing interest from institutional players. The number of shareholders has risen to 77,969, showcasing increasing retail participation. This diversified ownership structure enhances investor confidence and stability, as the significant promoter stake aligns management interests with those of shareholders. However, the declining promoter share from 71.14% in early 2023 to 60.93% in late 2025 may raise concerns regarding long-term control. The gradual increase in institutional holdings indicates a positive outlook from the investment community, reflecting confidence in Thyrocare’s growth trajectory and operational performance.
Outlook, Risks, and Final Insight
Thyrocare Technologies Ltd is well-positioned for continued growth in the healthcare sector, supported by strong financial metrics and a solid operational foundation. Potential strengths include its robust profitability, efficient operations, and minimal debt, which collectively enhance its competitive advantage. However, risks include reliance on a concentrated customer base and potential regulatory changes in the healthcare industry that could impact operations. Additionally, fluctuations in demand due to market competition present challenges. The outlook remains positive, provided the company continues to innovate and adapt to market dynamics. With strategic initiatives aimed at expanding service offerings and enhancing customer engagement, Thyrocare may further solidify its position as a leader in the medical services sector. The company’s ability to navigate emerging challenges while leveraging its strengths will be critical to sustaining growth and delivering value to shareholders.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 46.5 Cr. | 139 | 187/120 | 9.49 | 117 | 2.52 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.6 Cr. | 22.5 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.5 Cr. | 10.2 | 20.5/7.08 | 117 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 103 Cr. | 55.0 | 98.7/54.0 | 22.7 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.9 Cr. | 3.49 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 24,969.21 Cr | 666.72 | 87.64 | 93.18 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 125 | 117 | 125 | 124 | 136 | 123 | 141 | 144 | 163 | 153 | 174 | 179 | 202 |
| Expenses | 96 | 91 | 102 | 90 | 100 | 92 | 108 | 101 | 114 | 112 | 118 | 122 | 133 |
| Operating Profit | 30 | 26 | 23 | 33 | 37 | 31 | 34 | 42 | 49 | 40 | 56 | 57 | 69 |
| OPM % | 24% | 22% | 18% | 27% | 27% | 25% | 24% | 29% | 30% | 26% | 32% | 32% | 34% |
| Other Income | 1 | 1 | 2 | 0 | 2 | 2 | 3 | 3 | 2 | 4 | 5 | 4 | 2 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Depreciation | 8 | 9 | 9 | 9 | 9 | 11 | 10 | 9 | 10 | 15 | 12 | 9 | 10 |
| Profit before tax | 22 | 18 | 15 | 24 | 28 | 21 | 25 | 35 | 40 | 28 | 48 | 51 | 61 |
| Tax % | 35% | 28% | 33% | 31% | 28% | 28% | 23% | 28% | 27% | 32% | 54% | 29% | 29% |
| Net Profit | 14 | 13 | 10 | 17 | 20 | 15 | 19 | 25 | 30 | 19 | 22 | 36 | 43 |
| EPS in Rs | 0.90 | 0.80 | 0.63 | 1.05 | 1.28 | 0.94 | 1.21 | 1.58 | 1.86 | 1.20 | 1.38 | 2.27 | 2.71 |
Last Updated: December 28, 2025, 7:35 pm
Below is a detailed analysis of the quarterly data for Thyrocare Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 202.00 Cr.. The value appears strong and on an upward trend. It has increased from 179.00 Cr. (Jun 2025) to 202.00 Cr., marking an increase of 23.00 Cr..
- For Expenses, as of Sep 2025, the value is 133.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 122.00 Cr. (Jun 2025) to 133.00 Cr., marking an increase of 11.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Jun 2025) to 69.00 Cr., marking an increase of 12.00 Cr..
- For OPM %, as of Sep 2025, the value is 34.00%. The value appears strong and on an upward trend. It has increased from 32.00% (Jun 2025) to 34.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Jun 2025) to 61.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Sep 2025, the value is 29.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 29.00%.
- For Net Profit, as of Sep 2025, the value is 43.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Jun 2025) to 43.00 Cr., marking an increase of 7.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.71. The value appears strong and on an upward trend. It has increased from 2.27 (Jun 2025) to 2.71, marking an increase of 0.44.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:30 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 150 | 180 | 235 | 298 | 332 | 370 | 401 | 474 | 562 | 486 | 524 | 633 | 708 |
| Expenses | 81 | 109 | 140 | 182 | 193 | 222 | 233 | 304 | 330 | 371 | 388 | 446 | 486 |
| Operating Profit | 69 | 71 | 95 | 115 | 139 | 148 | 168 | 171 | 232 | 115 | 136 | 188 | 221 |
| OPM % | 46% | 40% | 40% | 39% | 42% | 40% | 42% | 36% | 41% | 24% | 26% | 30% | 31% |
| Other Income | 7 | 13 | 6 | -16 | 21 | 14 | -35 | 12 | 7 | 5 | 6 | 13 | 14 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 5 | 3 | 2 |
| Depreciation | 6 | 11 | 11 | 12 | 12 | 14 | 20 | 21 | 28 | 34 | 39 | 47 | 46 |
| Profit before tax | 69 | 73 | 89 | 87 | 148 | 147 | 112 | 161 | 207 | 81 | 98 | 151 | 188 |
| Tax % | 33% | 33% | 34% | 46% | 35% | 35% | 29% | 26% | 27% | 30% | 28% | 37% | |
| Net Profit | 46 | 49 | 59 | 47 | 96 | 95 | 79 | 120 | 152 | 57 | 71 | 96 | 120 |
| EPS in Rs | 14.07 | 3.25 | 3.64 | 2.90 | 5.96 | 6.01 | 5.00 | 7.55 | 9.58 | 3.59 | 4.48 | 6.02 | 7.56 |
| Dividend Payout % | 0% | 157% | 91% | 115% | 56% | 111% | 33% | 110% | 52% | 167% | 134% | 116% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.52% | 20.41% | -20.34% | 104.26% | -1.04% | -16.84% | 51.90% | 26.67% | -62.50% | 24.56% | 35.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | 13.89% | -40.75% | 124.59% | -105.30% | -15.80% | 68.74% | -25.23% | -89.17% | 87.06% | 10.65% |
Thyrocare Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 4% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -3% |
| 3 Years: | -15% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 27% |
| 1 Year: | 55% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 19% |
| 3 Years: | 14% |
| Last Year: | 17% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: January 7, 2026, 4:33 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves | 195 | 229 | 322 | 364 | 400 | 403 | 325 | 393 | 468 | 468 | 461 | 484 | 463 |
| Borrowings | 25 | 0 | 0 | 0 | 0 | 0 | 9 | 10 | 21 | 21 | 39 | 23 | 22 |
| Other Liabilities | 14 | 14 | 39 | 26 | 31 | 32 | 55 | 73 | 55 | 70 | 68 | 116 | 113 |
| Total Liabilities | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 | 676 | 651 |
| Fixed Assets | 87 | 83 | 93 | 89 | 103 | 108 | 112 | 119 | 149 | 157 | 159 | 158 | 160 |
| CWIP | 6 | 6 | 1 | 2 | 0 | 1 | 4 | 8 | 2 | 1 | 1 | 14 | 3 |
| Investments | 119 | 162 | 266 | 299 | 315 | 289 | 239 | 274 | 259 | 274 | 291 | 284 | 265 |
| Other Assets | 33 | 42 | 55 | 54 | 68 | 89 | 88 | 127 | 186 | 180 | 169 | 221 | 223 |
| Total Assets | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 | 676 | 651 |
Below is a detailed analysis of the balance sheet data for Thyrocare Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 53.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 53.00 Cr..
- For Reserves, as of Sep 2025, the value is 463.00 Cr.. The value appears to be declining and may need further review. It has decreased from 484.00 Cr. (Mar 2025) to 463.00 Cr., marking a decrease of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 23.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 113.00 Cr.. The value appears to be improving (decreasing). It has decreased from 116.00 Cr. (Mar 2025) to 113.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 651.00 Cr.. The value appears to be improving (decreasing). It has decreased from 676.00 Cr. (Mar 2025) to 651.00 Cr., marking a decrease of 25.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 158.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 265.00 Cr.. The value appears to be declining and may need further review. It has decreased from 284.00 Cr. (Mar 2025) to 265.00 Cr., marking a decrease of 19.00 Cr..
- For Other Assets, as of Sep 2025, the value is 223.00 Cr.. The value appears strong and on an upward trend. It has increased from 221.00 Cr. (Mar 2025) to 223.00 Cr., marking an increase of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 651.00 Cr.. The value appears to be declining and may need further review. It has decreased from 676.00 Cr. (Mar 2025) to 651.00 Cr., marking a decrease of 25.00 Cr..
Notably, the Reserves (463.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 44.00 | 71.00 | 95.00 | 115.00 | 139.00 | 148.00 | 159.00 | 161.00 | 211.00 | 94.00 | 97.00 | 165.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12 | 9 | 11 | 7 | 10 | 11 | 14 | 34 | 60 | 63 | 28 | 40 |
| Inventory Days | 54 | 47 | 54 | 64 | 66 | 54 | 60 | 50 | 54 | 63 | 106 | 93 |
| Days Payable | 13 | 5 | 8 | 4 | 23 | 19 | 62 | 48 | 30 | 52 | 83 | 141 |
| Cash Conversion Cycle | 53 | 51 | 57 | 68 | 53 | 46 | 12 | 37 | 84 | 74 | 51 | -9 |
| Working Capital Days | 22 | 52 | 15 | 28 | 11 | 4 | -12 | 7 | 45 | 34 | 14 | 18 |
| ROCE % | 33% | 27% | 27% | 29% | 33% | 31% | 36% | 37% | 41% | 15% | 18% | 26% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 5,167,803 | 0.37 | 256.17 | 1,722,601 | 2025-12-15 03:04:08 | 200% |
| Nippon India Pharma Fund | 4,392,120 | 2.57 | 217.72 | 1,548,692 | 2025-12-14 07:13:13 | 183.6% |
| HSBC Midcap Fund | 4,373,100 | 1.73 | 216.77 | 950,000 | 2025-12-14 07:13:13 | 360.33% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 2,873,886 | 0.91 | 142.46 | 1,033,015 | 2025-12-14 07:13:13 | 178.2% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 2,804,472 | 2.15 | 139.02 | 934,824 | 2025-12-14 07:13:13 | 200% |
| ICICI Prudential Dividend Yield Equity Fund | 1,909,800 | 1.49 | 94.67 | 636,600 | 2025-12-14 04:15:52 | 200% |
| HSBC Large & Mid Cap Fund | 1,737,570 | 1.85 | 86.13 | 434,594 | 2025-12-15 01:20:14 | 299.81% |
| ICICI Prudential Multicap Fund | 1,311,450 | 0.4 | 65.01 | 437,150 | 2025-12-14 07:13:13 | 200% |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 354,579 | 2.06 | 17.58 | N/A | N/A | N/A |
| Aditya Birla Sun Life Bal Bhavishya Yojna | 280,398 | 1.16 | 13.9 | 147,495 | 2025-12-14 07:13:13 | 90.11% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 17.13 | 13.42 | 12.16 | 33.30 | 21.41 |
| Diluted EPS (Rs.) | 17.08 | 13.40 | 12.14 | 33.25 | 21.37 |
| Cash EPS (Rs.) | 27.83 | 21.93 | 19.25 | 39.73 | 27.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 103.18 | 99.65 | 101.12 | 99.54 | 80.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 103.18 | 99.65 | 101.12 | 99.54 | 80.81 |
| Revenue From Operations / Share (Rs.) | 129.71 | 108.00 | 99.50 | 111.32 | 93.55 |
| PBDIT / Share (Rs.) | 38.72 | 27.72 | 24.27 | 49.93 | 34.74 |
| PBIT / Share (Rs.) | 28.29 | 18.85 | 16.96 | 43.53 | 29.02 |
| PBT / Share (Rs.) | 27.72 | 18.05 | 16.51 | 43.08 | 28.85 |
| Net Profit / Share (Rs.) | 17.40 | 13.05 | 11.94 | 33.33 | 21.41 |
| NP After MI And SOA / Share (Rs.) | 17.27 | 13.36 | 12.16 | 33.30 | 21.40 |
| PBDIT Margin (%) | 29.85 | 25.66 | 24.39 | 44.85 | 37.13 |
| PBIT Margin (%) | 21.81 | 17.44 | 17.04 | 39.10 | 31.01 |
| PBT Margin (%) | 21.36 | 16.71 | 16.59 | 38.70 | 30.83 |
| Net Profit Margin (%) | 13.41 | 12.08 | 11.99 | 29.94 | 22.89 |
| NP After MI And SOA Margin (%) | 13.31 | 12.37 | 12.22 | 29.91 | 22.87 |
| Return on Networth / Equity (%) | 16.73 | 13.43 | 12.04 | 33.45 | 26.48 |
| Return on Capital Employeed (%) | 26.26 | 18.03 | 16.15 | 42.39 | 34.03 |
| Return On Assets (%) | 13.20 | 10.98 | 10.17 | 28.98 | 20.73 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 1.03 | 0.89 | 0.79 | 0.98 | 0.94 |
| Current Ratio (X) | 2.77 | 3.08 | 3.54 | 4.18 | 2.50 |
| Quick Ratio (X) | 2.39 | 2.55 | 3.18 | 3.80 | 2.26 |
| Inventory Turnover Ratio (X) | 14.62 | 4.38 | 5.82 | 6.80 | 7.44 |
| Dividend Payout Ratio (NP) (%) | 104.15 | 134.63 | 123.29 | 45.02 | 46.69 |
| Dividend Payout Ratio (CP) (%) | 64.93 | 80.89 | 76.98 | 37.76 | 36.84 |
| Earning Retention Ratio (%) | -4.15 | -34.63 | -23.29 | 54.98 | 53.31 |
| Cash Earning Retention Ratio (%) | 35.07 | 19.11 | 23.02 | 62.24 | 63.16 |
| Interest Coverage Ratio (X) | 67.28 | 34.95 | 54.67 | 111.45 | 211.14 |
| Interest Coverage Ratio (Post Tax) (X) | 31.23 | 17.45 | 27.89 | 75.40 | 131.14 |
| Enterprise Value (Cr.) | 3550.20 | 3118.27 | 2246.85 | 4079.23 | 4758.17 |
| EV / Net Operating Revenue (X) | 5.17 | 5.45 | 4.27 | 6.93 | 9.62 |
| EV / EBITDA (X) | 17.30 | 21.24 | 17.49 | 15.44 | 25.90 |
| MarketCap / Net Operating Revenue (X) | 5.24 | 5.48 | 4.32 | 6.95 | 9.65 |
| Retention Ratios (%) | -4.15 | -34.63 | -23.29 | 54.97 | 53.30 |
| Price / BV (X) | 6.59 | 5.95 | 4.26 | 7.77 | 11.17 |
| Price / Net Operating Revenue (X) | 5.24 | 5.48 | 4.32 | 6.95 | 9.65 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 |
After reviewing the key financial ratios for Thyrocare Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.13. This value is within the healthy range. It has increased from 13.42 (Mar 24) to 17.13, marking an increase of 3.71.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.08. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 17.08, marking an increase of 3.68.
- For Cash EPS (Rs.), as of Mar 25, the value is 27.83. This value is within the healthy range. It has increased from 21.93 (Mar 24) to 27.83, marking an increase of 5.90.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 103.18. It has increased from 99.65 (Mar 24) to 103.18, marking an increase of 3.53.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 103.18. It has increased from 99.65 (Mar 24) to 103.18, marking an increase of 3.53.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 129.71. It has increased from 108.00 (Mar 24) to 129.71, marking an increase of 21.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 38.72. This value is within the healthy range. It has increased from 27.72 (Mar 24) to 38.72, marking an increase of 11.00.
- For PBIT / Share (Rs.), as of Mar 25, the value is 28.29. This value is within the healthy range. It has increased from 18.85 (Mar 24) to 28.29, marking an increase of 9.44.
- For PBT / Share (Rs.), as of Mar 25, the value is 27.72. This value is within the healthy range. It has increased from 18.05 (Mar 24) to 27.72, marking an increase of 9.67.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.40. This value is within the healthy range. It has increased from 13.05 (Mar 24) to 17.40, marking an increase of 4.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 17.27. This value is within the healthy range. It has increased from 13.36 (Mar 24) to 17.27, marking an increase of 3.91.
- For PBDIT Margin (%), as of Mar 25, the value is 29.85. This value is within the healthy range. It has increased from 25.66 (Mar 24) to 29.85, marking an increase of 4.19.
- For PBIT Margin (%), as of Mar 25, the value is 21.81. This value exceeds the healthy maximum of 20. It has increased from 17.44 (Mar 24) to 21.81, marking an increase of 4.37.
- For PBT Margin (%), as of Mar 25, the value is 21.36. This value is within the healthy range. It has increased from 16.71 (Mar 24) to 21.36, marking an increase of 4.65.
- For Net Profit Margin (%), as of Mar 25, the value is 13.41. This value exceeds the healthy maximum of 10. It has increased from 12.08 (Mar 24) to 13.41, marking an increase of 1.33.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 12.37 (Mar 24) to 13.31, marking an increase of 0.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.73. This value is within the healthy range. It has increased from 13.43 (Mar 24) to 16.73, marking an increase of 3.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 26.26. This value is within the healthy range. It has increased from 18.03 (Mar 24) to 26.26, marking an increase of 8.23.
- For Return On Assets (%), as of Mar 25, the value is 13.20. This value is within the healthy range. It has increased from 10.98 (Mar 24) to 13.20, marking an increase of 2.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.00, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.03. It has increased from 0.89 (Mar 24) to 1.03, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.77. This value is within the healthy range. It has decreased from 3.08 (Mar 24) to 2.77, marking a decrease of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 2.39. This value exceeds the healthy maximum of 2. It has decreased from 2.55 (Mar 24) to 2.39, marking a decrease of 0.16.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.62. This value exceeds the healthy maximum of 8. It has increased from 4.38 (Mar 24) to 14.62, marking an increase of 10.24.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 104.15. This value exceeds the healthy maximum of 50. It has decreased from 134.63 (Mar 24) to 104.15, marking a decrease of 30.48.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 64.93. This value exceeds the healthy maximum of 50. It has decreased from 80.89 (Mar 24) to 64.93, marking a decrease of 15.96.
- For Earning Retention Ratio (%), as of Mar 25, the value is -4.15. This value is below the healthy minimum of 40. It has increased from -34.63 (Mar 24) to -4.15, marking an increase of 30.48.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 35.07. This value is below the healthy minimum of 40. It has increased from 19.11 (Mar 24) to 35.07, marking an increase of 15.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 67.28. This value is within the healthy range. It has increased from 34.95 (Mar 24) to 67.28, marking an increase of 32.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 31.23. This value is within the healthy range. It has increased from 17.45 (Mar 24) to 31.23, marking an increase of 13.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,550.20. It has increased from 3,118.27 (Mar 24) to 3,550.20, marking an increase of 431.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.17. This value exceeds the healthy maximum of 3. It has decreased from 5.45 (Mar 24) to 5.17, marking a decrease of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 17.30. This value exceeds the healthy maximum of 15. It has decreased from 21.24 (Mar 24) to 17.30, marking a decrease of 3.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 5.24, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is -4.15. This value is below the healthy minimum of 30. It has increased from -34.63 (Mar 24) to -4.15, marking an increase of 30.48.
- For Price / BV (X), as of Mar 25, the value is 6.59. This value exceeds the healthy maximum of 3. It has increased from 5.95 (Mar 24) to 6.59, marking an increase of 0.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 5.24, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Thyrocare Technologies Ltd:
- Net Profit Margin: 13.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 26.26% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.73% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 31.23
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.39
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 62.9 (Industry average Stock P/E: 87.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | D/37-1, TTC Industrial Area, MIDC, Turbhe, New Mumbai Maharashtra 400703 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rahul Guha | Managing Director & CEO |
| Mr. Dharmil Sheth | Non Executive Director |
| Mr. Hardik Dedhia | Non Executive Director |
| Dr. Dhaval Shah | Non Executive Director |
| Dr.(Mrs.) Indumati Gopinathan | Independent Director |
| Dr.(Ms.) Prapti Gilada | Independent Director |
| Dr. Harshil Vora | Independent Director |
| Mr. Nishant A Shah | Independent Director |
| Mr. Anandh Sundar | Independent Director |
FAQ
What is the intrinsic value of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd's intrinsic value (as of 21 January 2026) is ₹275.41 which is 41.90% lower the current market price of ₹474.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹7,559 Cr. market cap, FY2025-2026 high/low of ₹538/219, reserves of ₹463 Cr, and liabilities of ₹651 Cr.
What is the Market Cap of Thyrocare Technologies Ltd?
The Market Cap of Thyrocare Technologies Ltd is 7,559 Cr..
What is the current Stock Price of Thyrocare Technologies Ltd as on 21 January 2026?
The current stock price of Thyrocare Technologies Ltd as on 21 January 2026 is ₹474.
What is the High / Low of Thyrocare Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Thyrocare Technologies Ltd stocks is ₹538/219.
What is the Stock P/E of Thyrocare Technologies Ltd?
The Stock P/E of Thyrocare Technologies Ltd is 62.9.
What is the Book Value of Thyrocare Technologies Ltd?
The Book Value of Thyrocare Technologies Ltd is 32.5.
What is the Dividend Yield of Thyrocare Technologies Ltd?
The Dividend Yield of Thyrocare Technologies Ltd is 1.48 %.
What is the ROCE of Thyrocare Technologies Ltd?
The ROCE of Thyrocare Technologies Ltd is 26.5 %.
What is the ROE of Thyrocare Technologies Ltd?
The ROE of Thyrocare Technologies Ltd is 17.4 %.
What is the Face Value of Thyrocare Technologies Ltd?
The Face Value of Thyrocare Technologies Ltd is 10.0.